Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2007-02-02

Last Posted Date: 2009-01-28

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 135

Registration Number: NCT00430651

Locations: 🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷
"Sotiria" General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases, Athens, Greece
🇬🇷
"Theagenion" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece

and more 7 locations

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Carcinoma
Invasive Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00429182

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Phase 1

Completed

Conditions: Ovarian Cancer
Testicular Germ Cell Tumor
Brain and Central Nervous System Tumors
Teratoma
Extragonadal Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: ifosfamide
Drug: paclitaxel
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-01-18

Last Posted Date: 2016-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT00423852

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Phase 1

Completed

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Bladder Cancer
Fallopian Tube Cancer

Interventions: Drug: belinostat
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-01-15

Last Posted Date: 2015-07-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 80

Registration Number: NCT00421889

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
Hematology & Oncology Specialists, LLC, Metairie, Louisiana, United States
🇬🇧
The Royal Marsden NHS Trust, Surrey, United Kingdom

and more 8 locations

Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-28

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 30

Registration Number: NCT00416676

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-28

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00417053

Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Terminated

Conditions: Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas

Interventions: Drug: bortezomib
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2006-12-28

Last Posted Date: 2019-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT00416793

Locations: 🇺🇸
MD Anderson Cancer Network, Houston, Texas, United States

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-12-22

Last Posted Date: 2011-07-08

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 14

Registration Number: NCT00415116

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Chemotherapy-Induced Thrombocytopenia
Solid Tumors
Thrombocytopenia
Lung Cancer
Oncology
Non-Small Cell Lung Cancer
Cancer
Lung Neoplasms

Interventions: Drug: Placebo
Biological: Romiplostim
Drug: Gemcitabine
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2006-12-19

Last Posted Date: 2013-10-24

Lead Sponsor: Amgen

Target Recruit Count: 63

Registration Number: NCT00413283

Locations: 🇵🇹
Research Site, Vila Nova de Gaia, Portugal

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-13

Last Posted Date: 2013-08-07

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 642

Registration Number: NCT00410631

Locations: 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪
Klinikum Dortmund, Dortmund, Germany
🇩🇪
Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany

and more 74 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy